Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment

Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults, with a short survival time even after aggressive therapy. Non-invasive surrogate biomarkers of therapy response may be relevant for improving patient survival. Previous work produced such biomarkers in preclinical GBM us...

Descripción completa

Detalles Bibliográficos
Autores principales: Arias-Ramos, Nuria, Ferrer-Font, Laura, Lope-Piedrafita, Silvia, Mocioiu, Victor, Julià-Sapé, Margarida, Pumarola, Martí, Arús, Carles, Candiota, Ana Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487991/
https://www.ncbi.nlm.nih.gov/pubmed/28524099
http://dx.doi.org/10.3390/metabo7020020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487991/
https://www.ncbi.nlm.nih.gov/pubmed/28524099
http://dx.doi.org/10.3390/metabo7020020

Ejemplares similares